This site is intended for healthcare professionals

GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases.

Read time: 1 mins
Last updated:29th Jul 2021
Published:6th Jul 2021
GlaxoSmithKline plc and Alector announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL 001 and AL 101) designed to elevate progranulin (PGRN) levels.
Condition: Dementia:Frontotemporal
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest